Fortune MNC 500 India 2026 edition
Rank#117- Total income
- ₹6,902 Cr
- Profit
- ₹-954 Cr
Last year #74
Viatris
Frankfurt, Germany Founded: 1998 • Age: 28 yrs Listed Acquired By Insud Pharma Fortune MNC 500 · #117
Branded pharmaceuticals are developed and commercialized by Viatris internationally.
Please enter your name.
Please enter a valid email address.
Please select an issue type.
Please add a few details about the issue.
About Viatris
Viatris is a publicly listed company based in Frankfurt (Germany) founded in 1998, and was acquired by Insud Pharma in March 2024. Branded pharmaceuticals are developed and commercialized by Viatris internationally. The company has 32,000 employees. Viatris has completed 3 acquisitions, including Aculys, Famy Life Sciences and Oyster Point Pharmaceuticals. Its chief executive, as recorded, is Scott A Smith. Its website viatris.com draws about 116 thousand monthly visits. Its Indian entity Mylan Laboratories Limited reported revenue of ₹7,504 Cr. Viatris offers products and services including Generic Medicines and Branded Products. Its focus areas include Traditional Pharmaceuticals.
Company details
Viatris was established in 1998 and is headquartered in Frankfurt, Germany, within the pharmaceuticals sector. Branded drugs are developed and marketed globally by the company, focusing on therapeutic solutions. Operations span research, manufacturing, and distribution across multiple regions. In 2022, annual revenues of 16.26 billion were achieved, alongside a net profit of 2.07 billion. Leadership is provided by CEO Scott A. Smith.
Viatris is ranked #117 on the Fortune MNC 500 India (2026).
Recognitions & Rankings of Viatris
Operational Areas
Key Metrics
- Indian entity revenue₹7,504 Cr
FY 2025 · -23% YoY
- Indian entity net loss-₹954 Cr
FY 2025 · -13% margin
- Indian entity EBITDA₹44.78 Cr
FY 2025 · 1% margin
- InvestorsInsud Pharma
& 1 more
- Employee Count32,000
- Investments & AcquisitionsAculys
& 2 more
- Acquired by
Associated legal entities of Viatris
Viatris operates through Mylan Laboratories Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Mylan Laboratories Limited CIN U24231TG1984PLC005146 | Active | 29 Nov 1984 | Hyderabad, Telangana | ₹7,504 Cr | 11,193 | 8 | View details |
Products & Services of Viatris
Viatris offers a comprehensive portfolio of products and services, including Generic Medicines and Branded Products.
Generic Medicines
Pharmaceuticals
Generic drugs are developed and distributed by Viatris across therapeutic areas to address noncommunicable and infectious diseases.
Branded Products
Healthcare Products
Branded generics and other medicines are offered by Viatris to enhance access in global markets.
Apps and channels of Viatris
its YouTube channel Viatris has 3.4K subscribers and 30 videos.
Viatris
Open channelVideos from Viatris
The most watched videos on Viatris's YouTube channel, Viatris (3.4K subscribers). Click a video to play it here.
Viatris En France | Découvrez notre site de Châtillon-sur-Chalaronne
Empathy in Africa: Bridging the Healthcare Gap
Behind the Medicine: How a Global Supply Chain Influences Access to Medicine
ListenWell Podcast S2:E4 Out of Breath: COPD and Mental Health
More on Viatris.
Investors in Viatris
Viatris has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Insud Pharma and Mylan.
All
Institutional
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Finished formulations, APIs, and monoclonal antibodies are developed and manufactured. | 1977 | insudpharma.com | Madrid, Spain | |
Mylan, part of Viatris, is focused on healthcare solutions. | meda.se |
Premium access
Investor details for Viatris
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Mylan Laboratories Limited (Viatris)
Mylan Laboratories Limited is the primary company behind Viatris. The board of Mylan Laboratories Limited currently have 6 directors; the longest-serving is Rajiv Malik, appointed in 2005. 23 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Rajiv Malik DIN 00120557 | Director | 28 Jul 2005 | 21 yrs 3 mo | Mylan Laboratories Limited |
| Sarada Kalyani Bhagawati DIN 02680074 | Whole-time director | 01 Nov 2014 | 12 yrs | Mylan Laboratories Limited |
| Nagaraj Goud Bodige DIN 10329289 | Nodal Officer | 22 Nov 2022 | 3 yrs 11 mo | Mylan Laboratories Limited |
| Akshay Nanda DIN 10517236 | Director | 01 Mar 2024 | 2 yrs 8 mo | Mylan Laboratories Limited |
| Arvind Shankar Kanda DIN 10560284 | Whole-time director | 28 Mar 2024 | 2 yrs 7 mo | Mylan Laboratories Limited |
| Ramya Suresh DIN 10603923 | Director | 25 Apr 2024 | 2 yrs 6 mo | Mylan Laboratories Limited |
People of Viatris
702 people are tracked at Viatris (283 in leadership, 8 in board & advisors, 411 in team); the tracked headcount is 32,000.
| Name | Role | Group |
|---|---|---|
Scott A Smith | CEO | Leadership |
Shawna Zoladz | Head Of Commercial Services, NA | Leadership |
Andrea Moore | Quality Director, Qp, RP | Leadership |
Claire Portefaix | Head Of Prescription Business Unit, Digital & Commercial Excellence | Leadership |
Patrick Schlebrowski | Head Of Business Unit Rx Promoted, Mylan Germany Gmbh (a Viatris Company) | Leadership |
Nuno Loureiro | Head Of Pharmacy Business Unit | Leadership |
Amanda Tolbert | Head Of Trade & Customs North America | Leadership |
Erika Maurer | HR Director Switzerland | Leadership |
Orla Fitzgerald | Head Of Digital Transformation & Commercial Excellence | Leadership |
Don Cornwell | Director | Leadership |
Tim Rouse | Director Respiratory R & D Project Leader | Leadership |
Tomasz Lorenz | Head Of Marketing Europe And Canada. (ad Interim) Head Of Marketing JANZ And Emerging Markets | Leadership |
Punyatoya Patnaik | Deputy General Manager | Leadership |
Michael Takla | Head Of Launch Excellence JANZ & Emerging Markets | Leadership |
Vincent Caron | Head Of Supply Chain & Operational Excellence | Leadership |
Darpan Chopra | General Manager Quality Control | Leadership |
Dan P. | Head Of Market Access And Value | Leadership |
Peter McCormick | Chief Supply Officer | Leadership |
Corinne Le Goff | Chief Commercial Officer | Leadership |
Tia Witt | Director, Global Strategic Projects — Commercial IT | Leadership |
682 more people are available in the full profile.
Premium access
Complete people profiles for Viatris
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Viatris
Viatris is a publicly listed company on the NASDAQ with ticker symbol VTRS in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date21 Apr 2021
- Listed onLSE: 0A5V
- Listed entityViatris Inc.
- Exchange sectorHealth technology
- ISINUS92556V1061
- Share price$17.25 (-1.65% on the day) · 2026-10-13
- Market capitalisation$19.81B
- EPS (diluted, trailing year)$-0.36
- Dividend yield2.74%
- Volume (last session)7,547,574
Financials of Viatris
Figures of Mylan Laboratories Limited, the primary company behind Viatris, for FY 2025. Revenue was ₹7,504 Cr (-23% year on year). Net loss was -₹954 Cr (-13% margin). EBITDA was ₹44.78 Cr (1% margin). Revenue has grown at a compounded annual rate of -14% over three years and -10% over five years.
- ₹7,504 CrRevenue · FY 2025 · -23% YoY
- -₹954 CrNet loss · -13% margin
- ₹44.78 CrEBITDA · 1% margin
- ₹48.70 CrPaid-up capital
- 11,193Employees (provident fund records)
- -14%Revenue CAGR, 3 years
- -10%Revenue CAGR, 5 years
Exchange-reported annual figures
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $14.29B | -$3.51B | $3.89B |
| 2024 | $14.71B | -$634.2M | $4.57B |
| 2023 | $15.38B | $54.7M | $4.73B |
| 2022 | $16.17B | $2.08B | $5.36B |
| 2021 | $17.86B | -$1.27B | $4.88B |
Balance sheet, profit and loss, cash flow and ratios of Mylan Laboratories Limited are on its company page.
Premium access
Detailed financial statements for Viatris
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Viatris
Viatris has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include Aculys, Famy Life Sciences and Oyster Point Pharmaceuticals.
Acquisitions
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Therapeutic medicines for neuropsychiatric and sleep disorders are developed. | aculys.com | Fujisawa, Japan | 2021 | Oct 2025 | •••• | |
Gene therapies for ophthalmological diseases are developed. | oysterpointrx.com | Princeton, United States | 2015 | Nov 2022 | •••• | |
Drug development services are offered for ophthalmology, oncology, and dermatology. | famylifesciences.com | Ahmedabad, India | 2008 | Nov 2022 | •••• |
Premium access
Complete acquisition details for Viatris
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Viatris
7 dated milestones of Viatris across 27 years, from founding to its latest funding, stage changes and deals.
- Founded Viatris is founded.
- Exit Acquired by Meda.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Famy Life Sciences.
- Acquisition Acquires Oyster Point Pharmaceuticals.
- Exit Acquired by Insud Pharma.
- Acquisition Acquires Aculys.
Web traffic of Viatris
The website of Viatris (viatris.com) receives about 115.7K visits a month and ranks #380,790 among all websites worldwide, #3,944 in Investing.
- Monthly visits115.7K
▲ 14.2% vs previous month
- Unique visitors48.1K
per month
- Global rank#380,790
among all websites
- Category rank#3,944
Finance · Investing
Visitor engagement
- Bounce rate39%
- Pages per visit2.0
- Average visit41 sec
- DevicesDesktop 33% · Mobile 67%
Upgrade to premium
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Viatris
Premium access
Complete news archive for Viatris
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Viatris
Viatris was founded in 1998.
Viatris is headquartered in Frankfurt, Germany. It is registered at Frankfurt, Hesse, Germany.
Scott A Smith is the CEO of Viatris, as recorded in our data.
Viatris has 32,000 employees.
The primary company behind Viatris, Mylan Laboratories Limited, reported revenue of ₹7,504 Cr for FY 2025, down 23% year on year.
Viatris was established in 1998 and is headquartered in Frankfurt, Germany, within the pharmaceuticals sector. Branded drugs are developed and marketed globally by the company, focusing on therapeutic solutions. Operations span research, manufacturing, and distribution across multiple regions. In 2022, annual revenues of 16.26 billion were achieved, alongside a net profit of 2.07 billion. Leadership is provided by CEO Scott A. Smith.
Viatris offers Generic Medicines and Branded Products.
Yes, Viatris is publicly traded on NASDAQ under the ticker symbol VTRS.
Viatris has made 3 acquisitions, including Aculys, Famy Life Sciences, and Oyster Point Pharmaceuticals.
Viatris has 2 investors. Key investors include Insud Pharma, and Mylan.
Viatris operates through Mylan Laboratories Limited.
Yes. Viatris was acquired by Meda in August 2005.